Non-Hodgkin's lymphomas: Clinical governance issues

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 3, 2002, Pages 577-596

  Fields, P A ^a   Goldstone, A H ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Clinical governance; Non Hodgkin's lymphoma

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

B CELL LYMPHOMA; CANCER SURVIVAL; CLINICAL PRACTICE; FOLLICULAR LYMPHOMA; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; IMAGING; LABORATORY TEST; LARGE CELL LYMPHOMA; LYMPHADENITIS; MEDICOLEGAL ASPECT; MORPHOLOGY; NATIONAL HEALTH SERVICE; NONHODGKIN LYMPHOMA; OOCYTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; SPERM PRESERVATION; STEM CELL TRANSPLANTATION; TUMOR BIOPSY; UNITED KINGDOM; ETHICS; INTERDISCIPLINARY COMMUNICATION; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; B CELL LEUKEMIA; CANCER CENTER; CANCER RECURRENCE; GOVERNMENT; HEALTH CARE DELIVERY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; QUALITY CONTROL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

GREAT BRITAIN; HUMANS; INTERDISCIPLINARY COMMUNICATION; LYMPHOMA, NON-HODGKIN; NATIONAL HEALTH PROGRAMS; QUALITY OF HEALTH CARE;

EID: 0036456919     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0219     Document Type: Article

References (38)

1. Cartwright RA, McNally R & Staines A. The increasing incidence of Non Hodgkin's lymphoma; the possible role of sunlight. Leukaemia and Lymphoma 1994; 14: 387-394.
2. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Department of Health. A First Class Service. Quality in the new NHS. HSC, 1998: 33. London: HMSO, 1998.
4. Department of Health. The new NHS. Modern, Dependable. London: HMSO, 1997.
5. Department of Health. Corporate Governance in NHS, Code of Conduct, Code of Accountability. London: HMSO, 1994.
6. Department of Health, 1995. A report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales (Calman, Hine Report). A policy framework for commissioning cancer services.
7. Department of Health. The NHS Cancer Plan. London. September, 2000.
8. The Royal College of Pathologists. Clinical Audit in Pathology. London: The Royal College of Pathologists, 1997.
9. Department of Health. Working for patients. Working paper 6. London: HMSO, 1989.
10. NHS Executive. Clinical audit in the NHS, 1996. Leeds: NHSE.
11. Department of Health, NHS information strategy. Information for health. An information strategy for the modern NHS 1998-2005. A national strategy for local implementation. London: HMSO, 1998.
12. British Committee for Standards in Haematology. Guidelines on diagnosis and therapy. Non-Hodgkin's lymphoma 2001.
13. Continuing Professional Development. Royal College of Pathologists. www.rcpath.org.
14. General Medical Council. Revalidation - the professional moves forwards. GMC News, 1999, Issue S.
15. The Royal College of Pathologists. Professional Standards Unit and Professional Performance Panel. January 2002, pp 1-7.
16. Department of Health. A First Class Service. Quality in the new NHS. HSC, 1998: 33. London: HMSO, 1998.
17. Clinical Pathology Accreditation: Revision of standards. April, 1999, pp 1-6. www.cpa-uk-demon.co.uk.
18. Harris NL, Jaffe EA, Dieblod J et al. World Health Organisation of Neoplastic Diseases of the Haemopoeitic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting - Airie House, Virginia, November 1997. Journal of Clinical Oncology 1999; 17: 3835-3849.
19. Dojcinov SD, Attanoos RL, O'Brien CJ et al. Central Pathological Review of lymphomas in Wales and the identification of diagnostic discrepancies, which impact on treatment. In Marcus R et al (ed.) The Effective Management of non-Hodgkin's Lymphoma, pp 33-51. London: Aesculapsius Medical Press, 2000.
20. Ramsay AD, Smith WJ & Isaacson PG. T cell rich B-cell lymphoma. American Journal of Surgical Pathology 1988; 12: 433-443.
21. Lennert K. Malignant Lymphomas other than Hodgkin's Disease. New York: Springer Verlag, 1978.
22. Prescott RJ, Wells S, Bisset DL et al. Audit of tumour histopathology reviewed by a regional oncology centre. Journal of Clinical Pathology 1995; 48: 245-249.
23. Benharroch D, Meguerian Bedoyan Z et al. ALK positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076-2084.
24. Jack AS & Morgan GJ. The development of haematopathology laboratories: a possible model for other pathology services. Journal of Pathology 1998; 194: 231-233.
25. Royal College of Physicians: the management of gonadal toxicity resulting from the treatment of adult cancer. Report of a working party of the joint Council for Clinical Oncology. Royal College of Physicians of London, 1998.
26. Fuks Z & Kaplan HS. Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas. Radiology 1973; 108: 675-684.
27. Reddy S, Saxena VS, Pellettiere EV et al. Stage I and II non-Hodgkin's lymphomas: long-term results of radiation therapy. International Journal of Radiation, Oncology, Biology, Physics 1989; 16: 687-692.
28. Sutcliffe SB, Gospodarowicz MK, Bush RS et al. Role of radiation therapy in localised non Hodgkin's lymphoma. Radiotherapy and Oncology 1985; 4: 211-235.
29. Harmans J, Krol A, van Groningne K et al. International prognostic index for aggressive non Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460-1463.
30. NHL Classification Project. A clinical evaluation of the international Lymphoma Study Group Classification of non Hodgkin's Lymphoma. Blood 1997; 89: 3903-3918.
31. Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas: watchful waiting versus aggressive combined modality treatment. Seminars in Haematology 1988; 25: 11-16.
32. Horning SJ & Rosenburg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New England Journal of Medicine 1984; 311: 1471-1475.
33. Keating NJ, McLaughin P, Cabinillas F et al. Low-grade non-Hodgkin's lymphoma - development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FMD). European Journal of Cancer Care 1997; 6(4 supplement): 21-26.
34. Mclaughin P, Hagemeister FB, Romaguera JF et al. Fludarabine, mitoxantrone and dexamethosone: an effective new regimen for indolent lymphoma. Journal of Clinical Oncology 1996; 14: 1262-1268.
35. Miller TP, Dahlberg S, Cassady R et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localised intermediate and high grade non Hodgkin's lymphoma. New England Journal of Medicine 1998; 339: 21-26.
36. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 2002; 346: 235-242.
37. Philip T, Guglielmi C, Hagenbeck A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin's lymphoma. New England Journal of Medicine 1995; 333: 1540-1545.
38. Philip T, Armitage JO, Spitzer G et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non Hodgkin's lymphoma. New England Journal of Medicine 1987; 316: 1493-1498.